Is It Too Late To Consider CVS Health (CVS) After Last Year’s 24% Share Price Gain

• Some investors may be asking whether CVS Health at around US$78.86 is offering good value right now, or if the easier gains have already been made.
• The stock has returned 2.7% over the last week and 8.3% over the last 30 days, with a 24.0% return over the past year but a small 1.6% decline year to date.
• Recent headlines have focused on CVS Health's positioning within US healthcare services and pharmacy benefits, as the company continues to attract attention as a major integrated player. This context has kept investor focus on how resilient its core business model is and what that might imply for long term value.
• CVS Health currently has a valuation score of 3/6. Next, you will see how different valuation methods line up on the stock, followed by a way to think about value that goes beyond the usual ratios and models.

CVS Health delivered 24.0% returns over the last year. See how this stacks up to the rest of the Healthcare industry.

Approach 1: CVS Health Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model projects the cash a business might generate in the future and then discounts those amounts back to today to estimate what the company could be worth right now.

For CVS Health, the latest twelve month free cash flow is about $7.57b. Using a 2 Stage Free Cash Flow to Equity model, analysts and extrapolated estimates point to projected free cash flow of $14.30b by 2030, with intermediate projections through 2035 supplied by a mix of analyst inputs and Simply Wall St extrapolations.

On this basis, the model arrives at an estimated intrinsic value of about $277.41 per share. Compared with the recent share price around $78.86, the DCF output indicates that the stock trades at a 71.6% discount to this intrinsic estimate. Within this framework, the model therefore suggests that the stock is materially undervalued.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests CVS Health is undervalued by 71.6%. Track this in your watchlist or portfolio, or discover 57 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for CVS Health.

Approach 2: CVS Health Price vs Earnings

For companies that are generating profits, the P/E ratio is a straightforward way to see how much you are paying for each dollar of earnings. A higher or lower P/E often reflects what the market thinks about a company’s growth potential and the risks around those earnings.

In general, faster growth and lower perceived risk can justify a higher “normal” or “fair” P/E, while slower growth or higher risk usually calls for a lower multiple. CVS Health currently trades on a P/E of 57.16x. That sits above both the Healthcare industry average of 23.32x and the peer average of 18.26x, so on simple comparisons the stock screens as more expensive than many alternatives in its space.

Simply Wall St’s Fair Ratio is a proprietary estimate of what CVS Health’s P/E “should” be, given factors such as its earnings growth profile, profit margins, industry, market cap and risk characteristics. Because it blends these elements, it can be more tailored than a broad industry or peer comparison. For CVS Health, the Fair Ratio is 39.40x, which is below the current 57.16x. This points to the shares trading above this modelled fair level.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your CVS Health Narrative

Earlier it was mentioned that there is an even better way to think about valuation, and on Simply Wall St that comes from Narratives. With Narratives, you and other investors attach a clear story to the numbers by setting your own assumptions for CVS Health’s revenue, earnings, margins and fair value. You can then compare that fair value with today’s price to decide whether the stock looks attractive, fully priced or expensive based on your view. Each Narrative lives on the Community page, updates automatically as fresh news or earnings arrive, and can range from more cautious cases that see fair value closer to about US$62 per share to more optimistic cases around US$104 or the analyst consensus near US$96.58. All of these reflect different beliefs about how CVS Health’s integrated healthcare model will play out over time.

For CVS Health however we will make it really easy for you with previews of two leading CVS Health Narratives:

🐂 CVS Health Bull Case

Fair value in this narrative: US$104.01 per share

Implied discount versus last close: about 24.2% below this fair value

Revenue growth assumption: 18.02%

• This bullish view sees CVS Health using its integrated model across insurance, pharmacy benefits, retail, and care delivery to rebuild earnings power even after recent restructuring charges and margin pressure.
• The Health Care Benefits segment, government contracts, and membership trends are central to the thesis, with a focus on premium revenues, medical membership, and investment income as key supports for the long term story.
• The narrative leans on a detailed DCF and P/E comparison with peers to argue that current pricing sits well below the author’s estimate of intrinsic value, while also highlighting execution risks around costs, acquisitions, and regulatory pressure.

🐻 CVS Health Bear Case

Fair value in this narrative: US$62.09 per share

Implied premium versus last close: about 27.0% above this fair value

Revenue growth assumption: 7.0%

• This more cautious view highlights that CVS Health’s integrated setup could create revenue and cost benefits, but sees meaningful uncertainty around whether those benefits will fully come through.
• Key risks include ongoing healthcare reform debates that could affect business economics, as well as pressure on physical retail stores as more consumers shift to online options.
• The author also flags that profit growth expectations may sit below some managed care peers, given the challenges facing the retail operations and the work required to refresh the store footprint.

These two Narratives frame a clear range for you, from a higher implied fair value that leans into CVS Health’s integrated care ambitions to a lower fair value that puts more weight on political, retail, and growth headwinds, and you can decide where your view fits between them using the To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for CVS Health on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Do you think there's more to the story for CVS Health? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com